The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin

Clinical article

Restricted access

Object

Heparin-induced thrombocytopenia Type II (HIT II) is a serious complication that occurs in 0.2–3% of patients treated with heparin and is associated with a high risk of thrombotic events. One center recently reported an incidence of HIT II of 15% in a population of patients with aneurysmal subarachnoid hemorrhage (aSAH). Because these patients are typically exposed to heparin during angiography, controversy exists regarding whether prophylaxis with enoxaparin rather than heparin affords any reduction in the risk of developing HIT II. In this study, the authors investigated the effect of heparin compared with enoxaparin on the incidence of HIT II in patients with aSAH.

Methods

The authors reviewed the medical records of 300 patients treated for aSAH who received thromboprophylaxis with either heparin or enoxaparin, and identified patients who developed HIT II. The incidences of HIT II in the 2 treatment groups were then compared.

Results

One hundred sixty-six patients with aSAH were treated with heparin, and 134 patients were treated with enoxaparin. Sixteen (5.3%) of 300 patients met the diagnostic criteria for HIT II. Of those treated with heparin, 8 (4.8%) of 166 developed HIT II, compared with 8 (6%) of 134 treated with enoxaparin (difference not significant).

Conclusions

The authors report a lower incidence of HIT II in patients with aSAH than has previously been reported. The data also suggest that patients with aSAH who receive heparin are at no greater risk of developing HIT II than those who receive enoxaparin. This finding challenges the merit of choosing enoxaparin rather than heparin for thromboprophylaxis in patients with a SAH.

Abbreviations used in this paper: aSAH = aneurysmal subarachnoid hemorrhage; DVT = deep venous thrombosis; HIT II = heparininduced thrombocytopenia Type II; ICU = intensive care unit; LMWH = low-molecular-weight heparin; SD = standard deviation.

Article Information

Address correspondence to: Grace H. Kim, M.D., Department of Neurological Surgery, Columbia College of Physicians and Surgeons, Neurological Institute of New York, 630 West 168th Street, Room 5-462, New York, New York 10032. email: ghkim9@yahoo.com.

Please include this information when citing this paper: published online October 31, 2008; DOI: 10.3171/2008.3.17480.

© AANS, except where prohibited by US copyright law.

Headings

References

1

Agnelli GPiovella FBuoncristiani PSeveri PPini MD'Angelo A: Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 339:80851998

2

Almeida JICoats RLiem TKSilver D: Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 27:3093161998

3

Amiral JBridey FDreyfus MVissoc AMFressinaud EWolf M: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95961992

4

Antman EMMorrow DAMcCabe CHMurphy SARuda MSadowski Z: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:147714882006

5

Baglin TP: Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. J Clin Pathol 54:2722742001

6

Black PMBaker MFSnook CP: Experience with external pneumatic calf compression in neurology and neurosurgery. Neurosurgery 18:4404441986

7

Brieger DBMak KHKottke-Marchant KTopol EJ: Heparininduced thrombocytopenia. J Am Coll Cardiol 31:144914591998

8

Chibbaro STacconi L: Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients. Surg Neurol [epub ahead of print]2008

9

Chong BH: Heparin-induced thrombocytopenia. Br J Haematol 89:4314391995

10

Chong BHCastaldi PA: Heparin-induced thrombocytopenia: further studies of the effects of heparin-dependent antibodies on platelets. Br J Haematol 64:3473541986

11

Chong BHCastaldi PA: Platelet proaggregating effect of heparin: possible mechanism for non-immune heparin-associated thrombocytopenia. Aust N Z J Med 16:7157161986

12

Chong BHFawaz IChesterman CNBerndt MC: Heparininduced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 73:2352401989

13

Chong BHGrace CSRozenberg MC: Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets. Br J Haematol 49:5315401981

14

Chong BHPitney WRCastaldi PA: Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 2:124612491982

15

Cines DBKaywin PBina MTomaski ASchreiber AD: Heparin-associated thrombocytopenia. N Engl J Med 303:788 7951980

16

Creekmore FMOderda GMPendleton RCBrixner DI: Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 26:143814452006

17

Doty JRAlving BMMcDonnell DEOndra SL: Heparin-associated thrombocytopenia in the neurosurgical patient. Neurosurgery 19:69721986

18

Fabris FAhmad SCella GJeske WPWalenga JMFareed J: Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications–a review Arch Pathol Lab Med 124:165716662000

19

Fabris FLuzzatto GStefani PMGirolami BCella GGirolami A: Heparin-induced thrombocytopenia. Haematologica 85:72812000

20

Frim DMBarker FG IIPoletti CEHamilton AJ: Postoperative low-dose heparin decreases thromboembolic complications in neurosurgical patients. Neurosurgery 30:8308331992

21

Ganzer DGutezeit AMayer G: [Potentials risks in drug prevention of thrombosis–low-molecular-weight heparin versus standard heparin.]. Z Orthop Ihre Grenzgeb 137:4574611999. (Ger)

22

Gerlach RScheuer TBeck JWoszczyk ASeifert VRaabe A: Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: results of a prospective study. Neurosurgery 53:102810352003

23

Girolami BPrandoni PStefani PMTanduo CSabbion PEichler P: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101:295529592003

24

Greinacher A: Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost 21:1061161995

25

Greinacher AEichler PLietz TWarkentin TE: Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 106:292129222005

26

Greinacher AFarner BKroll HKohlmann TWarkentin TEEichler P: Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients Thromb Haemost 94:1321352005

27

Greinacher APotzsch BAmiral JDummel VEichner AMueller-Eckhardt C: Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71:2472511994

28

Hamilton MGHull RDPineo GF: Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery 34:2802961994

29

Harbrecht UBastians BKredteck AHanfland PKlockgether TPohl C: Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin. Neurology 62:6576592004

30

Hoh BLAghi MPryor JCOgilvy CS: Heparin-induced thrombocytopenia Type II in subarachnoid hemorrhage patients: incidence and complications. Neurosurgery 57:2432482005

31

Januzzi JL JrJang IK: Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. J Thromb Thrombolysis 7:2592641999

32

Kelton JGSmith JWWarkentin TEHayward CPDenomme GAHorsewood P: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:323232391994

33

Kongable GLLanzino GGermanson TPTruskowski LLAlves WMTorner JC: Gender-related differences in aneurysmal subarachnoid hemorrhage. J Neurosurg 84:43481996

34

Lewis BEWallis DEBerkowitz SDMatthai WHFareed JWalenga JM: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:183818432001

35

Leyvraz PFBachmann FHoek JBuller HRPostel MSamama M: Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 303:5435481991

36

Locke CFDooley JGerber J: Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar Thromb J 3:42005

37

Lubenow NEichler PLietz TGreinacher A: Lepirudin in patients with heparin-induced thrombocytopenia—results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3:2428 24362005

38

Mahlfeld KFranke JSchaeper OKayser RGrasshoff H: [Heparin-induced thrombocytopenia as a complication of postoperative prevention of thromboembolism with unfractionated heparin/low molecular weight heparin after hip and knee prosthesis implantation.]. Unfallchirurg 105:3273312002. (Ger)

39

Martel NLee JWells PS: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710 27152005

40

Nurmohamed MTRosendaal FRBuller HRDekker EHommes DWVandenbroucke JP: Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 340:1521561992

41

Parney IFSteinke DE: Heparin-induced thrombocytopenia and thrombosis following subarachnoid hemorrhage Case report. J Neurosurg 93:1361392000

42

Pohl CKredteck ABastians BHanfland PKlockgether THarbrecht U: Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin. Neurology 64:128512872005

43

Pouplard CMay MAIochmann SAmiral JVissac AMMarchand M: Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99:253025361999

44

Roberts BRosato FERosato EF: Heparin—a cause of arterial emboli?. Surgery 55:8038081964

45

Rogers LA: Postendarterectomy heparin-induced thrombocytopenia Case report. J Neurosurg 69:6326341988

46

Schmitt BPAdelman B: Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 305:2082151993

47

Szucs TDSchramm W: The cost-effectiveness of low-molecular-weight heparin vs unfractionated heparin in general and orthopaedic surgery: an analysis for the German healthcare system. Pharmacol Res 40:83891999

48

Walenga JMJeske WPPrechel MMBacher PBakhos M: Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin Thromb Hemost 30:1 Suppl69802004

49

Wallis DELewis BEWalenga JM: Failure of current strategies in the prevention of thrombosis in patients with heparininduced thrombocytopenia: a clinician's perspective. Semin Thromb Hemost 25:1 Suppl371999

50

Warkentin TECook DJ: Heparin, low molecular weight heparin, and heparin-induced thrombocytopenia in the ICU. Crit Care Clin 21:5135292005

51

Warkentin TEGreinacher A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:3 Suppl311S337S2004

52

Warkentin TEKelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:5025071996

53

Warkentin TEKelton JG: Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:128612922001

54

Warkentin TELevine MNHirsh JHorsewood PRoberts RSGent M: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:133013351995

55

Warkentin TERoberts RSHirsh JKelton JG: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 163:251825242003

56

Warkentin TESheppard JAHorsewood PSimpson PJMoore JCKelton JG: Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:170317082000

57

Weismann RETobin RW: Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 76:2192271958

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 85 85 18
Full Text Views 121 121 3
PDF Downloads 49 49 5
EPUB Downloads 0 0 0

PubMed

Google Scholar